Lars Fruergaard Jørgensen, CEO of Novo Nordisk, announces that the company is facing demand outstripping supply, a problem it plans to gradually improve over the next year. The ramp-up in production.
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.